ICI-based therapies: A new strategy for oral potentially malignant disorders

Oral Oncol. 2023 May:140:106388. doi: 10.1016/j.oraloncology.2023.106388. Epub 2023 Apr 11.

Abstract

Oral potentially malignant disorders (OPMDs) are linked with an escalated risk of developing cancers, particularly oral squamous cell carcinoma (OSCC). Since prevailing therapies cannot effectively forestall the exacerbation and recurrence of OPMDs, halting their malignant progression is paramount. The immune checkpoint serves as a cardinal regulator of the immune response and the primary cause of adaptive immunological resistance. Although the exact mechanism remains elusive, elevated expression of multiple immune checkpoints in OPMDs and OSCC relative to healthy oral mucosa has been ascertained. This review delves into the immunosuppressive microenvironment of OPMDs, the expression of diverse immune checkpoints such as programmed death receptor-1 (PD-1) and programmed death receptor-1 ligand (PD-L1) in OPMDs, and the potential application of corresponding inhibitors. In addition, synergistic strategies incorporating combined immune checkpoint inhibitors, such as cGAS-STING, costimulatory molecules, cancer vaccines, and hydrogels, are discussed to gain a more comprehensive understanding of the role and application of immune checkpoint inhibitors (ICIs) in oral carcinogenesis.

Keywords: ICIs; Immunosuppressive microenvironment; OPMDs; PD-1; cGAS-STING.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • B7-H1 Antigen / metabolism
  • Carcinoma, Squamous Cell* / drug therapy
  • Head and Neck Neoplasms*
  • Humans
  • Immune Checkpoint Inhibitors
  • Mouth Diseases*
  • Mouth Neoplasms* / drug therapy
  • Mouth Neoplasms* / pathology
  • Precancerous Conditions*
  • Receptors, Death Domain
  • Squamous Cell Carcinoma of Head and Neck / drug therapy
  • Tumor Microenvironment

Substances

  • Immune Checkpoint Inhibitors
  • B7-H1 Antigen
  • Receptors, Death Domain